Literature DB >> 29422809

Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis.

Kosaku Nanki1, Shinta Mizuno1, Katsuyoshi Matsuoka2, Keiko Ono1, Shinya Sugimoto1, Hiroki Kiyohara1, Mari Arai1, Moeko Nakashima1, Kozue Takeshita1, Keiichiro Saigusa1, Mitsutoshi Senoh3, Tadashi Fukuda3, Makoto Naganuma1, Haru Kato3, Wataru Suda4, Masahira Hattori5, Takanori Kanai1.   

Abstract

Fecal microbiota transplantation (FMT) has been reported as a safe and effective therapy in patients with refractory and recurrent Clostridium difficile infection (CDI). FMT has also been reported as a promising therapy in patients with ulcerative colitis (UC). Both, CDI and UC, are believed to be caused by dysbiosis, such as altered compositions or decreased diversity of the intestinal microbiota. This report describes a patient with UC in remission with a second recurrent episode of CDI, who was treated with FMT. A single FMT performed via colonoscopy completely resolved the patient's diarrhea and eradicated C. difficile bacteriologically without any severe complications. Molecular biological analysis of the patient's fecal microbiota showed that FMT could dramatically change the altered composition of intestinal microbiota and restore its diversity. Despite the restoration of the intestinal microbiota, FMT could not prevent a relapse of UC in this patient. However, it improved the intestinal symptoms of CDI and could prevent further recurrences of CDI.

Entities:  

Keywords:  Clostridium difficile; Colitis, ulcerative; Fecal microbiota transplantation

Year:  2018        PMID: 29422809      PMCID: PMC5797261          DOI: 10.5217/ir.2018.16.1.142

Source DB:  PubMed          Journal:  Intest Res        ISSN: 1598-9100


  20 in total

1.  European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.

Authors:  S B Debast; M P Bauer; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2014-03       Impact factor: 8.067

2.  Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system.

Authors:  Wendy S Garrett; Graham M Lord; Shivesh Punit; Geanncarlo Lugo-Villarino; Sarkis K Mazmanian; Susumu Ito; Jonathan N Glickman; Laurie H Glimcher
Journal:  Cell       Date:  2007-10-05       Impact factor: 41.582

Review 3.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

4.  Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.

Authors:  Paul Moayyedi; Michael G Surette; Peter T Kim; Josie Libertucci; Melanie Wolfe; Catherine Onischi; David Armstrong; John K Marshall; Zain Kassam; Walter Reinisch; Christine H Lee
Journal:  Gastroenterology       Date:  2015-04-07       Impact factor: 22.682

Review 5.  Fecal microbiota transplantation for gastrointestinal diseases.

Authors:  Katsuyoshi Matsuoka; Shinta Mizuno; Atsushi Hayashi; Tadakazu Hisamatsu; Makoto Naganuma; Takanori Kanai
Journal:  Keio J Med       Date:  2014-12-15

6.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

Review 7.  American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection.

Authors:  Lawrence J Brandt
Journal:  Am J Gastroenterol       Date:  2013-01-15       Impact factor: 10.864

8.  Impact of Clostridium difficile on inflammatory bowel disease.

Authors:  Mazen Issa; Aravind Vijayapal; Mary Beth Graham; Dawn B Beaulieu; Mary F Otterson; Sarah Lundeen; Susan Skaros; Lydia R Weber; Richard A Komorowski; Josh F Knox; Jeanne Emmons; Jasmohan S Bajaj; David G Binion
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

9.  Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.

Authors:  Preetika Sinh; Terrence A Barrett; Laura Yun
Journal:  Gastroenterol Res Pract       Date:  2011-09-12       Impact factor: 2.260

10.  Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing.

Authors:  Seok-Won Kim; Wataru Suda; Sangwan Kim; Kenshiro Oshima; Shinji Fukuda; Hiroshi Ohno; Hidetoshi Morita; Masahira Hattori
Journal:  DNA Res       Date:  2013-04-09       Impact factor: 4.458

View more
  1 in total

Review 1.  Management of Clostridioides difficile infection in patients with inflammatory bowel disease.

Authors:  Sahil Khanna
Journal:  Intest Res       Date:  2020-08-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.